Avalo Therapeutics reports on May 8 carrying one of the most contested short-interest profiles in small-cap biotech.
The bear trade is substantial. Short interest has climbed to 30.7% of the free float — up 29% over the past month — making this one of the more heavily shorted names in the sector. Borrowing availability is tight: the lending pool has been near or fully exhausted for most of April, with availability only recently loosening slightly, touching 91% utilization as of May 4 after running at 100% for extended stretches. Despite all that borrow pressure, the cost to borrow remains remarkably low at just 1.6% annualised — a signal that supply has kept pace with demand even as the short position grew. The ORTEX short score of 78.7 ranks in the 4th percentile of the universe, flagging this as an extremely high-conviction short. Against that, the stock surged 18% on Tuesday and is up 26% on the week, leaving short sellers sitting on meaningful mark-to-market losses heading into the print.
Options traders are incrementally more cautious than they were a month ago, though not dramatically so. The put/call ratio at 0.92 is modestly above its 20-day average of 0.86 — barely one standard deviation above the mean — suggesting options positioning reflects measured hedging rather than outright fear. That's a notable contrast to the short book: the bearish conviction appears far more concentrated in the equity lending market than in derivatives.
The analyst community is constructive and has been getting more so. Wolfe Research initiated with an Outperform at a $48 target on April 9, and Citizens came in at $52 on April 6 — both in the weeks since the last print. BTIG has reiterated its Buy at $40. The consensus sits at 11 buy ratings and a mean target near $40, a significant premium to the current $16.26. The bull case centres on AVTX-009's Phase 2 results in hidradenitis suppurativa and the potential commercial differentiation of targeting IL-1β. Bears point to a crowded IL-1β space, the challenge of beating established IL-17 inhibitors, a PDUFA probability of approval cited around 35%, and the company's negative earnings yield. With a P/E ratio in negative territory and an EV just under $170 million, the stock is a pure pipeline call — valuation multiples are beside the point until efficacy data can speak for themselves.
Insider activity skews modestly negative. The CFO, Christopher Sullivan, has sold shares repeatedly through April and into late April at prices between roughly $13 and $18. The net 90-day insider flow is positive in share terms — primarily from awards — but the pattern of CFO open-market sales into the recent rally is worth noting. On the institutional side, FMR (Fidelity) and T. Rowe Price both built material new positions in the most recent reporting period, with T. Rowe adding nearly 1.45 million shares. That accumulation from two major healthcare-focused allocators provides a counterweight to the insider selling picture.
The May 8 print will test whether AVTX-009 efficacy data — or any clinical update — can give 30% short interest a reason to cover, or whether the bears who built positions through April find their conviction validated.
See the live data behind this article on ORTEX.
Open AVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
